|
Q-1388
|
Wednesday, June 17, 2026 |
With regard to the Minister of Health’s statement during Question Period on June 8, 2026 where she stated that “there were governance issues with Canada Health Infoway”: what specific “governance issues” was the Minister referring to? |
Awaiting response |
Monday, September 21, 2026 |
|
Q-1385
|
Wednesday, June 17, 2026 |
With regard to Canada's commitments under the 2016 United Nations Political Declaration on HIV and AIDS and the 2021 United Nations Political Declaration on HIV and AIDS: (a) how has Canada's Human Immunodeficiency Virus incidence rate changed since 2016, broken down by (i) year, (ii) province or territory, (iii) population; (b) since 2016, what specific federal policy changes have been adopted to advance the 2030 goal of ending Acquired Immunodeficiency Syndrome as a public health threat, including, for each, the (i) date adopted, (ii) responsible department or agency, (iii) description of the policy change, (iv) measurable outcomes intended; (c) how does Canada's Human Immunodeficiency Virus incidence rate trend since 2016 compared to that of other countries with similar Human Immunodeficiency Virus epidemics and healthcare systems, including (i) the United Kingdom, (ii) Australia; (d) does the Public Health Agency of Canada estimate that Canada met the 2020 targets set out in the 2016 political declaration, and, if not, which targets were missed and by what margin; (e) does the Public Health Agency of Canada estimate that Canada is on track to meet the 2025 targets set out in the 2021 political declaration, and, if not, which targets are at risk of being missed and by what margin; and (f) does the Public Health Agency of Canada estimate that Canada will achieve the goal of ending Acquired Immunodeficiency Syndrome as a public health threat by 2030? |
Awaiting response |
Monday, September 21, 2026 |
|
Q-1374
|
Tuesday, June 16, 2026 |
With regard to steering committee meetings for Park's Canada's planned National Park Reserve in the South Okanagan-Similkameen, since 2016: what are the details of each meeting, including, for each, the (i) date, (ii) agenda items, (iii) titles of the attendees, (iv) summary of each item decided and decision made? |
Awaiting response |
Monday, September 21, 2026 |
|
Q-1373
|
Tuesday, June 16, 2026 |
With regard to Parks Canada's planned National Park Reserve in the South Okanagan-Similkameen: (a) what are the annual expenditures specifically dedicated to the planning, consultation and negotiation of the proposed national park reserve, broken down by year since 2016; (b) for the annual expenditures in fiscal years 2021-22 to 2025-26 and broken down by year, what is the cost of (i) staffing, (ii) transportation, (iii) accommodations, (iv) meals and per diems, (v) third-party contracts, (vi) office supplies, (vii) rentals, (viii) other expenses broken down by type; and (c) what are the details of all contracts signed by Parks Canada in relation to (a) since 2017, including, for each, the (i) date, (ii) original contract value, (iii) latest contract value, (iv) vendor, (v) description of the goods or services, (vi) manner in which the contract was awarded (sole-sourced or competitive bid)? |
Awaiting response |
Monday, September 21, 2026 |
|
Q-1186
|
Friday, May 1, 2026 |
With regard to differences between Canadian and international regulation of food dyes and additives, and data related to food products sold in Canada with synthetic dyes: (a) has Health Canada conducted any review of the United States Food and Drug Administration's 2025 announcement to phase out petroleum-based synthetic food dyes, including FD&C Red No. 3, FD&C Red No. 40, FD&C Yellow No. 5, FD&C Yellow No. 6, FD&C Blue No. 1, FD&C Blue No. 2, and FD&C Green No. 3, and, if so, what were the findings; (b) does Health Canada plan to phase out any of the products in (a), and, if so, what are the details, including the timeline of such a plan; (c) what specific consultations, if any, has Health Canada held regarding international alignment on food dye and additive regulations since 2020, and what are the details of each consultation, including the (i) date, (ii) location, (iii) individuals involved; (d) for each of FD&C Red No. 3 (erythrosine), FD&C Red No. 40 (allura red), FD&C Yellow No. 5 (tartrazine), FD&C Yellow No. 6 (sunset yellow), FD&C Blue No. 1 (brilliant blue), FD&C Blue No. 2 (indigotine), and FD&C Green No. 3 (fast green), what is the most recent data held by Health Canada or the Canadian Food Inspection Agency on the (i) number of food products sold in Canada containing the dye, (ii) average concentration in products containing the dye, (iii) categories of food products in which the dye most commonly appears, (iv) date the data was collected; and (e) what are the details, including the findings, of any assessments Health Canada has conducted on the dietary exposure of Canadian children to synthetic food dyes? |
Answered |
Wednesday, June 17, 2026 |
|
Q-1145
|
Tuesday, April 28, 2026 |
With regard to Parks Canada’s planned South Okanagan-Similkameen National Park Reserve: (a) what are the timelines regarding the negotiation progress and establishment agreement for the proposed national park reserve; (b) what is the present departmental timeline for the proposed national park reserve; (c) what are the annual expenditures specifically dedicated to the planning, consultation and negotiation of the proposed national park reserve; (d) what are the staffing allocations (full-time equivalents) specifically dedicated to the planning, consultation and negotiation of the proposed national park reserve; (e) what were the dates, locations and topics discussed during the meetings of the tripartite negotiation committees involving Parks Canada, the Government of British Columbia, and the Syilx/Okanagan Nation regarding the proposed national park reserve; (f) what is the budget for the park’s projected infrastructure costs, if approved; (g) what is the projected analysis of the park’s expected tourism activity, broken down by visitor numbers and annual revenues; (h) what is the land valuation of private property that overlaps with the proposed park's boundaries; (i) what is the number of private properties that overlap with the proposed park's boundaries, broken down by title owner and ranked by land size; (j) what are the details, including the dates, participants, and types of consultations, for all in-person and online consultations which have taken place related to the proposal; (k) what are the categories of feedback from consultations that have been completed, ranked by frequency; and (l) does the government have funds allocated for this national park reserve, that will become available upon approval, and, if so, how much, and what is the breakdown of how those funds will be used? |
Answered |
Monday, June 15, 2026 |
|
Q-1144
|
Monday, April 27, 2026 |
With regard to contracts provided by the government to Agfa HealthCare Inc. since January 1, 2016, broken down by department, agency, Crown corporation, or other government entity: (a) what is the total amount spent on contracts; and (b) what are the details of all such contracts, including (i) the amount, (ii) the vendor, (iii) the date and duration, (iv) the description of the goods or services provided, (v) the topics related to the goods or services provided, (vi) the specific goals or objectives related to the contract, (vii) whether or not the goals or objectives were met, (viii) whether the contract was sole-sourced or tendered? |
Answered |
Friday, June 12, 2026 |
|
Q-1142
|
Monday, April 27, 2026 |
With regard to contracts provided to TELUS and TELUS Health, by Health Canada, the Public Health Agency of Canada or the Canadian Food Inspection Agency, since January 1, 2016: (a) what is the total amount spent on contracts; and (b) what are the details of all such contracts, including (i) the amount, (ii) the vendor, (iii) the date and duration, (iv) the description of the goods or services provided, (v) the topics related to the goods or services provided, (vi) the specific goals or objectives related to the contract, (vii) whether or not the goals or objectives were met, (viii) whether the contract was sole-sourced or tendered? |
Answered |
Friday, June 12, 2026 |
